Get started
Author

Patricia W. Bedard

Observed names: Patricia Bedard, Patricia W. Bedard
ORCID: 0009-0005-6121-3784
Observed ORCID: 0009-0005-6121-3784
OpenAlex ID: A5072698697
Endothelin Receptor Antagonists in Kidney Disease
2023 · Irene Martínez-Díaz, Nerea Martos, et al. · International Journal of Molecular Sciences · 68
PDF
International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology
2023 · Masaomi Nangaku, A. Richard Kitching, et al. · Kidney International · 39
PDF
Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease
2024 · Donald E. Kohan, Patricia W. Bedard, et al. · Clinical Science · 38
Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS
2024 · Georgina Gyarmati, Urvi Nikhil Shroff, et al. · JCI Insight · 17
PDF
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
2025 · Jennifer Yee, Wu Gong, et al. · Clinical Journal of the American Society of Nephrology · 8
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
2024 · Howard Trachtman, Jai Radhakrishnan, et al. · Kidney International Reports · 8
PDF
Sparsentan Improves Glomerular Endothelial and Podocyte Functions and Augments Protective Tissue Repair in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)
2022 · Georgina Gyarmati, Sachin K. Deepak, et al. · Journal of the American Society of Nephrology · 8
MO255: Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS)
2022 · Patricia Bedard, Celia Jenkinson, et al. · Nephrology Dialysis Transplantation · 6
PDF
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety
2023 · Bruce M. Hendry, Donald E. Kohan, et al. · Journal of the American Society of Nephrology · 4
Framework for precision medicine in focal segmental glomerulosclerosis: Translation of sparsentan-responsive genes in a rat model to kidney disease associated proteins in biofluids
2025 · Sean Eddy, Viji Nair, et al. · medRxiv · 3
PDF
Fc 016sparsentan Improves Glomerular Blood Flow and Augments Protective Tissue Remodeling in Mouse Models of Focal Segmental Glomerulosclerosis (fsgs)
2021 · Georgina Gyarmati, Urvi Shroff, et al. · Nephrology Dialysis Transplantation · 3
The dual endothelin A and angiotensin II type 1 receptor antagonist sparsentan (FILSPARI®) exhibits a safe nonclinical male fertility toxicity profile
2024 · Patricia W. Bedard, Francesca Pretto, et al. · Regulatory Toxicology and Pharmacology · 1
Sparsentan (SPAR) in Participants with FSGS and Collagen Type IV Alpha 3-5 Chain (COL4A3-5) Variants
2025 · Jennifer Lai Yee, Howard Trachtman, et al. · Journal of the American Society of Nephrology
Wcn24-846 Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety
2024 · Bruce Hendry, Donald Kohan, et al. · Kidney International Reports
Development of a Treatment Response Prediction Strategy for Sparsentan in Glomerular Disease
2022 · Sean Eddy, Felix H. Eichinger, et al. · Journal of the American Society of Nephrology
Works count: 15
Citation count: 203
H-index: 7
I10-index: 4
Year
Topic
Type